Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Gene Therapy to Target CD22 for Acute Lymphocytic Leukemia and Non-Hodgkin Lymphoma by Hebei Senlang Biotechnology for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
Gene Therapy to Target CD22 for Acute Lymphocytic Leukemia and Non-Hodgkin Lymphoma is under clinical development by Hebei Senlang Biotechnology...